Literature DB >> 32312722

SMARCA family of genes.

Runjan Chetty1, Stefano Serra2.   

Abstract

The SMARCA subgroup of genes belong to the SWI1/SNF1 family that are responsible chromatin remodelling and repair. Inactivating mutations in the main SMARCA genes A2 and A4 lead to loss of expression of their respective proteins within the nucleus and, as such have characterised a set of malignancies that are underpinned by SMARCA-deficiency.The morphology of these tumours ranges from small to large epithelioid cells, giant cells and rhabdoid cells. The rhabdoid cells are frequently present in these tumours but are not a sine qua non for the diagnosis. Most of these tumours are undifferentiated or dedifferentiated, high-grade pleomorphic carcinomas. Focally, areas of better differentiation can be seen. The initial description of a SMARCA4-deficient malignancy was the small cell carcinoma of the ovary, hypercalcaemic type. Subsequently, tumours fitting this characteristic morphology and immunophenotype have been described in the lung, thoracic cavity, endometrium and sinonasal tract, gastrointestinal tract and kidney. Immunohistochemical loss of SMARCA2 and SMARCA4 may occur concomitantly or independently of each other.SMARCA-deficient malignant tumours represent a unique subset of tumours with typical morphological and immunohistochemical findings. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cancer; cancer genetics; genetics

Mesh:

Substances:

Year:  2020        PMID: 32312722     DOI: 10.1136/jclinpath-2020-206451

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  15 in total

Review 1.  Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-deficient undifferentiated tumors.

Authors:  Kyriakos Chatzopoulos; Jennifer M Boland
Journal:  Virchows Arch       Date:  2021-01-06       Impact factor: 4.064

Review 2.  Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients.

Authors:  Subasri Armon; Paul Hofman; Marius Ilié
Journal:  Cells       Date:  2021-07-29       Impact factor: 6.600

Review 3.  Untangling the web of intratumour heterogeneity.

Authors:  Zheqi Li; Marco Seehawer; Kornelia Polyak
Journal:  Nat Cell Biol       Date:  2022-08-08       Impact factor: 28.213

4.  Molecular, clinicopathological characteristics and surgical results of resectable SMARCA4-deficient thoracic tumors.

Authors:  Haohua Teng; Chunyu Ji; Jizhuang Luo; Bowen Ding; Alessio Campisi; Tangbing Chen
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-19       Impact factor: 4.322

5.  Diagnostic, Prognostic, and Immunological Roles of HELLS in Pan-Cancer: A Bioinformatics Analysis.

Authors:  Xiao Liang; Linji Li; Yuchao Fan
Journal:  Front Immunol       Date:  2022-06-14       Impact factor: 8.786

6.  A Pan-Cancer Analysis of SMARCA4 Alterations in Human Cancers.

Authors:  Ling Peng; Jisheng Li; Jie Wu; Bin Xu; Zhiqiang Wang; Georgios Giamas; Justin Stebbing; Zhentao Yu
Journal:  Front Immunol       Date:  2021-10-04       Impact factor: 7.561

Review 7.  SMARCA4-Deficient Undifferentiated Tumor of Lung Mass-A Rare Tumor With the Rarer Occurrence of Brain Metastasis: A Case Report and Review of the Literature.

Authors:  Ruchi Yadav; Lishi Sun; Muhammad Salyana; Minkin Eric; Vladimir Gotlieb; Jen C Wang
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec

8.  Cross-species analysis of viral nucleic acid interacting proteins identifies TAOKs as innate immune regulators.

Authors:  Friederike L Pennemann; Assel Mussabekova; Christian Urban; Alexey Stukalov; Line Lykke Andersen; Vincent Grass; Teresa Maria Lavacca; Cathleen Holze; Lila Oubraham; Yasmine Benamrouche; Enrico Girardi; Rasha E Boulos; Rune Hartmann; Giulio Superti-Furga; Matthias Habjan; Jean-Luc Imler; Carine Meignin; Andreas Pichlmair
Journal:  Nat Commun       Date:  2021-12-01       Impact factor: 14.919

9.  HELLS serves as a poor prognostic biomarker and its downregulation reserves the malignant phenotype in pancreatic cancer.

Authors:  Feng-Jiao Wang; Yan-Hua Jing; Chien-Shan Cheng; Zhang-Qi Cao; Ju-Ying Jiao; Zhen Chen
Journal:  BMC Med Genomics       Date:  2021-07-27       Impact factor: 3.063

10.  Case Report: Multicentric Reticulohistiocytosis Associated With Posterior Mediastinal Adenosquamous Carcinoma, Antinuclear Antibody Positivity and Lupus Anticoagulant Positivity.

Authors:  Ziyi Tang; Xiangpeng Wang; Zijing Xia; Zhongming Wang; Yi Zhao; Yi Liu
Journal:  Front Immunol       Date:  2022-01-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.